Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There is currently no consensus on how best to manage refractory immune thrombocytopenic purpura (ITP). In part, this reflects the need for individualized treatment due to the wide spectrum of patients' requirements and responsiveness to therapies. The objective of this review is to provide a clinically useful guide to current management strategies. This article suggests investigations to identify factors that may exacerbate thrombocytopenia and underlie poor therapeutic responses, and highlights emerging therapies, including the thrombopoietic agents, which are anticipated to dramatically alter the natural history of "refractory" ITP. Morbidity, mortality and heath-related quality of life are also discussed.

Original publication

DOI

10.1111/j.1365-2141.2008.07275.x

Type

Journal article

Journal

Br J Haematol

Publication Date

10/2008

Volume

143

Pages

16 - 26

Keywords

Antibodies, Monoclonal, Antibodies, Monoclonal, Murine-Derived, Cyclophosphamide, Diagnosis, Differential, Humans, Immunoglobulins, Intravenous, Immunosuppressive Agents, Purpura, Thrombocytopenic, Quality of Life, Receptors, Thrombopoietin, Rho(D) Immune Globulin, Rituximab, Splenectomy, Thrombocytopenia